Key result
Late-onset durvalumab-associated myocarditis, occurring seven months after initiation for non-small-cell lung cancer, was successfully treated with corticosteroid therapy.
Case Report (n=1)
This case highlights the potential for late-onset myocarditis following durvalumab administration and its successful management with corticosteroids.
Answers are grounded in this paper and cite their sources.
May warrant myocarditis vigilance with durvalumab in NSCLC; leaves open incidence, predictors, and surveillance needs.
We herein report a 66-year-old man with locally advanced non-small-cell lung cancer (NSCLC) who developed durvalumab-associated myocarditis. The patient underwent durvalumab administration every two weeks following concurrent chemoradiotherapy, without any adverse events or apparent disease progression. He presented with fatigue and dyspnea on exertion seven months after the first administration. Myocarditis was suspected based on laboratory data, an electrocardiogram, echocardiography, and magnetic resonance imaging findings. The definitive diagnosis was confirmed by a myocardial biopsy. Myocarditis was alleviated by cessation of durvalumab and corticosteroid therapy. This is a noteworthy case to describe late-onset myocarditis following the administration of durvalumab for NSCLC.
No takes yet. Share an insight, caveat, or question.
Maetani et al. (2021) conducted a case report in Durvalumab-associated myocarditis in non-small-cell lung cancer (n=1). Corticosteroid therapy was evaluated on Clinical recovery from myocarditis. Late-onset durvalumab-associated myocarditis, occurring seven months after initiation for non-small-cell lung cancer, was successfully treated with corticosteroid therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: